Merck & Co., Inc. (MRK) has sought FDA approval for its blockbuster cancer medication Keytruda in yet another setting. This time, it is for the approval of Keytruda plus chemotherapy as treatment for primary advanced or recurrent endometrial carcinoma and a decision is expected on June 21, 2024.In the indication of endometrial carcinoma, Keytruda is already approved as a single agent and in combination with Eisai’s Lenvima.In the first quarter of 2024, the drug generated sales of $6.9 billion, an increase of 20% over the year-ago quarter.MRK closed Wednesday’s trading at $125.90, down 0.15%.